{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T06:14:42Z","timestamp":1778652882800,"version":"3.51.4"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prognostic evaluation of invasive pulmonary aspergillosis (IPA) in non-neutropenic patients remains clinically challenging. While galactomannan (GM) testing in serum and bronchoalveolar lavage fluid (BALF) aids in diagnosis, the prognostic significance of concurrent positivity in both compartments is not well-established. This study aimed to determine whether concurrent pretreatment GM positivity serves as an independent predictor of 30-day all-cause mortality in non-neutropenic IPA patients without underlying malignancy or solid organ transplantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a single-center, retrospective cohort study including 162 patients with proven or probable IPA admitted between February 2018 and February 2025. Patients were stratified into two groups based on stringent, predefined criteria: the GM-positive group (concurrent pretreatment serum GM index \u2265 0.7 and BALF GM index \u2265 0.8,\n                      <jats:italic>n<\/jats:italic>\n                      = 81) and the GM-negative group (both indices below these diagnostic thresholds,\n                      <jats:italic>n<\/jats:italic>\n                      = 81). All patients received standardized first-line antifungal therapy (voriconazole). The primary outcome was 30-day all-cause mortality. Survival analysis was performed using Kaplan-Meier estimates and Cox proportional hazards models, with adjustment for relevant clinical confounders.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall 30-day mortality was 29.6% (48\/162). Mortality was significantly higher in the GM-positive group compared to the GM-negative group (45.7% vs. 13.6%,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Multivariable Cox regression analysis confirmed that concurrent pretreatment GM positivity was independently associated with increased mortality (adjusted hazard ratio [HR] = 3.07; 95% confidence interval [CI], 1.5\u20136.29;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.002), after adjusting for factors including APACHE II score and key laboratory parameters.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In non-neutropenic IPA patients without classic immunocompromising conditions (e.g., malignancy or solid organ transplantation), concurrent pretreatment positivity for both serum and BALF GM is an independent prognostic marker for increased 30-day all-cause mortality. This combined assessment may serve as a valuable tool for early risk stratification, potentially helping to identify a high-risk subgroup that could benefit from more vigilant monitoring and individualized management strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1809671","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:53:02Z","timestamp":1778651582000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Concurrent pretreatment serum and BALF galactomannan positivity as a prognostic indicator in non-neutropenic invasive pulmonary aspergillosis without malignancy or solid organ transplantation: a retrospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"DeZhu","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Chongqing University Central Hospital","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Chongqing University Central Hospital","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YangLingXi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Chongqing University Central Hospital","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XiaoYing","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JinWei","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Chongqing University Central Hospital","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YanMei","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Chongqing University Central Hospital","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WeiDuo","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Chongqing University Central Hospital","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases-estimate precision.","volume":"3","author":"Bongomin","year":"2017","journal-title":"J Fungi."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/j.idc.2025.01.002","article-title":"Invasive Aspergillosis in the current era.","volume":"39","author":"Herrera","year":"2025","journal-title":"Infect Dis Clin North Am"},{"key":"B3","first-page":"82","article-title":"Aspergilosis invasiva: definiciones, diagn\u00f3stico y tratamiento [Invasive aspergillosis: definitions, diagnosis, and treatment].","volume":"83","author":"Lamberto","year":"2023","journal-title":"Medicina."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0060725","DOI":"10.1128\/spectrum.00607-25","article-title":"Development and validation of a machine learning-based diagnostic model for identifying nonneutropenic invasive pulmonary aspergillosis in suspected patients: a multicenter cohort study.","volume":"13","author":"Wang","year":"2025","journal-title":"Microbiol Spectr"},{"key":"B5","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S2213-2600(18)30274-1","article-title":"Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study.","volume":"6","author":"Schauwvlieghe","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/apm.13316","article-title":"Invasive pulmonary aspergillosis in the intensive care unit: current challenges and best practices.","volume":"131","author":"Gaffney","year":"2023","journal-title":"APMIS."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium.","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1093\/cid\/ciaa1786","article-title":"Defining galactomannan positivity in the updated EORTC\/MSGERC consensus definitions of invasive fungal diseases.","volume":"72","author":"Mercier","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"106159","DOI":"10.1016\/j.jinf.2024.106159","article-title":"Performance of the galactomannan test for the diagnosis of invasive pulmonary aspergillosis using non-invasive proximal airway samples.","volume":"88","author":"Chun","year":"2024","journal-title":"J Infect"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e43347","DOI":"10.1371\/journal.pone.0043347","article-title":"Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis.","volume":"7","author":"Zou","year":"2012","journal-title":"PLoS One."},{"key":"B11","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/mmy\/myw102","article-title":"Galactomannan testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis.","volume":"55","author":"Eigl","year":"2017","journal-title":"Med Mycol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"115274","DOI":"10.1016\/j.diagmicrobio.2020.115274","article-title":"Diagnostic value of galactomannan in serum and bronchoalveolar lavage fluid for invasive pulmonary aspergillosis in non-neutropenic patients.","volume":"99","author":"Wu","year":"2021","journal-title":"Diagn Microbiol Infect Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3760\/cma.j.issn.2095-4352.2019.03.014","article-title":"[Diagnostic value of the combinations of bronchoalveolar lavage fluid galactomannan test and serum galactomannan test in invasive pulmonary aspergillosis].","volume":"31","author":"Liu","year":"2019","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5434589","DOI":"10.1155\/2020\/5434589","article-title":"Diagnostic accuracy of bronchoalveolar lavage fluid galactomannan for invasive aspergillosis.","volume":"2020","author":"Cao","year":"2020","journal-title":"Biomed Res Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"943691","DOI":"10.1155\/2015\/943691","article-title":"The diagnosis of invasive and noninvasive pulmonary aspergillosis by serum and bronchoalveolar lavage fluid galactomannan assay.","volume":"2015","author":"Zhang","year":"2015","journal-title":"Biomed Res Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/myc.13269","article-title":"Diagnostic yield of a bronchoalveolar lavage fluid galactomannan assay in patients with negative serum galactomannan results suspected to have invasive pulmonary aspergillosis.","volume":"64","author":"Lim","year":"2021","journal-title":"Mycoses."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0122921","DOI":"10.1128\/JCM.01229-21","article-title":"Aspergillus test profiles and mortality in critically Ill COVID-19 patients.","volume":"59","author":"Erg\u00fcn","year":"2015","journal-title":"J Clin Microbiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0229821","DOI":"10.1128\/jcm.02298-21","article-title":"Prognostic impact of bronchoalveolar lavage fluid galactomannan and Aspergillus culture results on survival in COVID-19 intensive care unit patients: a post hoc analysis from the European Confederation of Medical Mycology (ECMM) COVID-19-associated pulmonary aspergillosis Study.","volume":"60","author":"Giacobbe","year":"2022","journal-title":"J Clin Microbiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13613-021-00827-3","article-title":"New clinical algorithm including fungal biomarkers to better diagnose probable invasive pulmonary aspergillosis in ICU.","volume":"11","author":"Hamam","year":"2021","journal-title":"Ann Intensive Care."},{"key":"B20","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1128\/JCM.05356-11","article-title":"Detection and measurement of fungal burden in a guinea pig model of invasive pulmonary aspergillosis by novel quantitative nested real-time PCR compared with galactomannan and (1,3)-\u03b2-D-glucan detection.","volume":"50","author":"Lengerova","year":"2012","journal-title":"J Clin Microbiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"106720","DOI":"10.1016\/j.rmed.2021.106720","article-title":"Mortality outcomes associated with invasive aspergillosis among acute exacerbation of chronic obstructive pulmonary disease patient population.","volume":"191","author":"Mir","year":"2022","journal-title":"Respir Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.chest.2023.09.019","article-title":"Prevalence, risk factors, clinical features, and outcome of influenza-associated pulmonary aspergillosis in critically ill patients: a systematic review and meta-analysis.","volume":"165","author":"Lu","year":"2024","journal-title":"Chest."},{"key":"B23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1086\/505870","article-title":"Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey.","volume":"43","author":"Cornillet","year":"2006","journal-title":"Clin Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e3606","DOI":"10.1093\/cid\/ciaa1065","article-title":"Epidemiology of invasive pulmonary aspergillosis among intubated patients with COVID-19: a prospective study.","volume":"73","author":"Bartoletti","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/thorax-2023-220002","article-title":"COVID-19-associated pulmonary aspergillosis in mechanically ventilated patients: a prospective, multicentre UK study.","volume":"79","author":"Hurt","year":"2023","journal-title":"Thorax"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/cid\/cit393","article-title":"The serum galactomannan index predicts mortality in hematopoietic stem cell transplant recipients with invasive aspergillosis.","volume":"57","author":"Fisher","year":"2013","journal-title":"Clin Infect Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"31389","DOI":"10.1038\/s41598-024-82806-9","article-title":"Metagenomic next-generation sequencing and galactomannan testing for the diagnosis of invasive pulmonary aspergillosis.","volume":"14","author":"Yang","year":"2024","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"631461","DOI":"10.3389\/fmed.2021.631461","article-title":"The clinical characteristics of patients with nonneutropenic invasive pulmonary aspergillosis.","volume":"8","author":"Liu","year":"2021","journal-title":"Front Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.cmi.2023.05.012","article-title":"How to use direct microscopy for diagnosing fungal infections.","volume":"29","author":"Knoll","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e0294524","DOI":"10.1128\/spectrum.02945-24","article-title":"Pentraxin-3 as a novel prognostic biomarker in non-neutropenic invasive pulmonary aspergillosis patients.","volume":"13","author":"Sun","year":"2025","journal-title":"Microbiol Spectr"},{"key":"B31","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1179\/joc.2011.23.5.290","article-title":"Invasive pulmonary aspergillosis in non-neutropenic patients: analysis of a 14-month prospective clinical experience.","volume":"23","author":"Russo","year":"2011","journal-title":"J Chemother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"R138","DOI":"10.1186\/cc11443","article-title":"Role of galactomannan determinations in bronchoalveolar lavage fluid samples from critically ill patients with chronic obstructive pulmonary disease for the diagnosis of invasive pulmonary aspergillosis: a prospective study.","volume":"16","author":"He","year":"2012","journal-title":"Crit Care."},{"key":"B33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/23744235.2023.2273381","article-title":"Influenza-associated invasive aspergillosis in patients admitted to the intensive care unit in Sweden: a prospective multicentre cohort study.","volume":"56","author":"Krifors","year":"2024","journal-title":"Infect Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1294971","DOI":"10.3389\/fcimb.2024.1294971","article-title":"Improved diagnostic markers for invasive pulmonary aspergillosis in COPD patients.","volume":"14","author":"Long","year":"2024","journal-title":"Front Cell Infect Microbiol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1809671\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:53:04Z","timestamp":1778651584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1809671\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":34,"alternative-id":["10.3389\/fmed.2026.1809671"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1809671","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"article-number":"1809671"}}